Pfs25 is a sexual stage antigen of Plasmodium falciparum that is expressed on the surface
of zygote and ookinete forms of the parasite. Monoclonal antibodies directed against native …

Transmission-blocking vaccines based on sexual-stage surface antigens of Plasmodium
falciparum may assist in the control of this lethal form of human malaria. Two vaccine …

Malaria transmission-blocking vaccination can effectively reduce and/or eliminate
transmission of parasites from the human host to the mosquito vector. The immunity …

Each of the four epidermal growth factor (EGF)-like domains of the Plasmodium falciparum
sexual-stage antigen Pfs25 has been individually expressed as a yeast-secreted …

Antibodies to Pfs28 block Plasmodium falciparum transmission and when combined with
antibodies to Pfs25 provide synergy in blocking transmission. Pfs28 and Pfs25 are …

Development of a Plasmodium falciparum (Pf) transmission blocking vaccine (TBV) has the
potential to significantly impact malaria control. Antibodies elicited against sexual stage …

Antibodies to Pfs25, a cysteine-rich 25-kDa protein present on the surface of Plasmodium
falciparum zygotes, can completely block the transmission of malaria parasites when mixed …

Plasmodium falciparum is transmitted to a new host after completing its sexual cycle within a
mosquito. Developing vaccines against the parasite sexual stages is a critical component in …

Immunological intervention, in addition to vector control and malaria chemotherapy, will be
needed to stop the resurgence of malaria, a disease with a devastating impact on the health …

Pfs48/45, a member of a Plasmodium-specific protein family, displays conformation-
dependent epitopes and is an important target for malaria transmission-blocking (TB) …